[Chemotherapy of esophageal carcinoma].
In metastatic esophageal cancer, single agent or combination chemotherapy induces short remissions in only a minority of patients. Therefore, only selected patients should be treated. More than half of patients with locoregional disease will experience significant improvement through cisplatinum-based combination chemotherapy. However, this has so far not shown itself to influence overall survivaL. Combination chemo-radiotherapy is superior to radiotherapy alone in locoregional disease. Studies in operable esophageal cancer comparing chemo-radiotherapy with surgery alone have not so far been reported.
Abteilung für Onkologie, Kantonsspital Basel.
R
R
Herrmann
D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000556:secondary; D006801:Humans; D011379:Prognosis
D000970:Antineoplastic Agents
Chemotherapie des Osophaguskarzinoms.